A population-based cohort study from Japan found that even virus-negative participants with an ALT level exceeding 30 IU/L had a statistically higher risk of HCC than virus-positive patients with an ALT level under 30 IU/L [29]. The gene discussed is GPT; the disease is hepatocellular carcinoma.